S. Negrier, B. Escudier, C. Lasset, J. Y. Douillard, J. Savary et al., Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie, N. Engl. J. Med, vol.338, pp.1272-1278, 1998.

R. Figlin, C. Sternberg, and C. G. Wood, Novel agents and approaches for advanced renal cell carcinoma, J. Urol, vol.188, pp.707-715, 2012.

M. B. Atkins, J. I. Clark, and D. I. Quinn, Immune checkpoint inhibitors in advanced renal cell carcinoma: Experience to date and future directions, Ann. Oncol. Off. J. Eur. Soc. Med Oncol, vol.28, pp.1484-1494, 2017.

R. J. Motzer, K. Penkov, J. Haanen, B. Rini, L. Albiges et al., Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.380, pp.1103-1115, 2019.

B. I. Rini, E. R. Plimack, V. Stus, R. Gafanov, R. Hawkins et al., Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.380, pp.1116-1127, 2019.

D. Cella, V. Grunwald, B. Escudier, H. J. Hammers, S. George et al., Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): A randomised, Lancet Oncol, vol.20, pp.297-310, 2019.

M. J. Garnett, E. J. Edelman, S. J. Heidorn, C. D. Greenman, A. Dastur et al., Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, vol.483, pp.570-575, 2012.

J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.483, pp.603-607, 2012.

R. H. Shoemaker, The NCI60 human tumour cell line anticancer drug screen, Nat. Rev. Cancer, vol.6, pp.813-823, 2006.

A. Basu, N. E. Bodycombe, J. H. Cheah, E. V. Price, K. Liu et al., An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules, Cell, vol.154, pp.1151-1161, 2013.

S. L. Holbeck, J. M. Collins, and J. H. Doroshow, Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines, Mol. Cancer Ther, vol.9, pp.1451-1460, 2010.

M. J. Garnett and U. Mcdermott, The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response, Curr. Opin. Genet. Dev, vol.24, pp.114-119, 2014.

M. Van-de-wetering, H. E. Francies, J. M. Francis, G. Bounova, F. Iorio et al., Prospective derivation of a living organoid biobank of colorectal cancer patients, Cell, vol.161, pp.933-945, 2015.

F. Iorio, T. A. Knijnenburg, D. J. Vis, G. R. Bignell, M. P. Menden et al., Landscape of Pharmacogenomic Interactions in Cancer. Cell, vol.166, pp.740-754, 2016.

J. Koerfer, S. Kallendrusch, F. Merz, C. Wittekind, C. Kubick et al., Organotypic slice cultures of human gastric and esophagogastric junction cancer, Cancer Med, vol.5, pp.1444-1453, 2016.

F. Merz, F. Gaunitz, F. Dehghani, C. Renner, J. Meixensberger et al., Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments, Neuro Oncol, vol.15, pp.670-681, 2013.

W. Senkowski, X. Zhang, M. H. Olofsson, R. Isacson, U. Hoglund et al., Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer, Mol. Cancer Ther, vol.14, pp.1504-1516, 2015.

N. Sachs and H. Clevers, Organoid cultures for the analysis of cancer phenotypes, Curr. Opin. Genet. Dev, vol.24, pp.68-73, 2014.

F. Weeber, S. N. Ooft, K. K. Dijkstra, and E. E. Voest, Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery, Cell Chem. Biol, vol.24, pp.1092-1100, 2017.

M. Bleijs, M. Van-de-wetering, H. Clevers, and J. Drost, Xenograft and organoid model systems in cancer research, EMBO J, vol.38, 2019.

M. A. Lancaster, M. Renner, C. A. Martin, D. Wenzel, L. S. Bicknell et al., Cerebral organoids model human brain development and microcephaly, Nature, vol.501, pp.373-379, 2013.

C. Pauli, B. D. Hopkins, D. Prandi, R. Shaw, T. Fedrizzi et al., Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine, vol.7, pp.462-477, 2017.

H. Lang, C. Beraud, A. Bethry, S. Danilin, V. Lindner et al., Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma, Oncotarget, vol.7, pp.59336-59359, 2016.

K. M. Morgan, G. M. Riedlinger, J. Rosenfeld, S. Ganesan, and S. R. Pine, Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine, Front. Oncol, vol.7, issue.2, 2017.

H. Maeda and M. Khatami, Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs, Clin. Transl. Med, vol.7, issue.11, 2018.

C. C. Wong, K. W. Cheng, and B. Rigas, Preclinical predictors of anticancer drug efficacy: Critical assessment with emphasis on whether nanomolar potency should be required of candidate agents, J. Pharmacol. Exp. Ther, vol.341, pp.572-578, 2012.

C. Ward, J. Meehan, M. Gray, I. H. Kunkler, S. P. Langdon et al., Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment, Curr. Top. Microbiol. Immunol, 2019.

R. B. Altman, Predicting cancer drug response: Advancing the DREAM, Cancer Discov, vol.5, pp.237-238, 2015.

C. Guyot, C. Combe, H. Clouzeau-girard, V. Moronvalle-halley, and A. Desmouliere, Specific activation of the different fibrogenic cells in rat cultured liver slices mimicking in vivo situations, Virchows Arch, vol.450, pp.503-512, 2007.

K. L. Schmeichel and M. J. Bissell, Modeling tissue-specific signaling and organ function in three dimensions, J. Cell. Sci, vol.116, pp.2377-2388, 2003.

V. Vaira, G. Fedele, S. Pyne, E. Fasoli, G. Zadra et al., Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors, Proc. Natl. Acad. Sci, vol.107, pp.8352-8356, 2010.

R. De-hoogt, M. F. Estrada, S. Vidic, E. J. Davies, A. Osswald et al., Protocols and characterization data for 2D, 3D, and slice-based tumor models from the PREDECT project, 2017.

S. Misra, C. F. Moro, M. Del-chiaro, S. Pouso, A. Sebestyen et al., Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma, Sci. Rep, vol.9, p.2133, 2019.

M. M. Gerlach, F. Merz, G. Wichmann, C. Kubick, C. Wittekind et al., Bechmann, I. Slice cultures from head and neck squamous cell carcinoma: A novel test system for drug susceptibility and mechanisms of resistance, Br. J. Cancer, vol.110, pp.479-488, 2014.

A. Marciniak, C. M. Cohrs, V. Tsata, J. A. Chouinard, C. Selck et al., Using pancreas tissue slices for in situ studies of islet of Langerhans and acinar cell biology, Nat. Protoc, vol.9, pp.2809-2822, 2014.

V. Rebours, M. Albuquerque, A. Sauvanet, P. Ruszniewski, P. Levy et al., Hypoxia pathways and cellular stress activate pancreatic stellate cells: Development of an organotypic culture model of thick slices of normal human pancreas, PLoS ONE, vol.8, 2013.

C. Kang, Y. Qiao, G. Li, K. Baechle, P. Camelliti et al., Human Organotypic Cultured Cardiac Slices: New Platform For High Throughput Preclinical Human, Trials. Sci. Rep, 2016.

T. Jiang, C. Zhou, and S. Ren, Role of IL-2 in cancer immunotherapy, Oncoimmunology, vol.5, 2016.

C. Roelants, S. Giacosa, C. Pillet, R. Bussat, P. Champelovier et al., Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma, Oncotarget, vol.9, pp.30066-30078, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02176916

C. J. Ricketts and W. M. Linehan, Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma, Cell, vol.173, pp.540-542, 2018.

W. G. Kaelin and . Jr, The von Hippel-Lindau tumour suppressor protein: O 2 sensing and cancer, Nat. Rev. Cancer, vol.8, pp.865-873, 2008.

C. J. Ricketts, D. R. Crooks, and W. M. Linehan, Targeting HIF2alpha in Clear-Cell Renal Cell Carcinoma, Cancer Cell, vol.30, pp.515-517, 2016.

W. S. Webster, C. M. Lohse, R. H. Thompson, H. Dong, X. Frigola et al., Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival, Cancer, vol.107, pp.46-53, 2006.

L. Vuong, R. R. Kotecha, M. H. Voss, and A. A. Hakimi, Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma, Cancer Discov, vol.9, pp.1349-1357, 2019.

V. B. Kraus, Biomarkers as drug development tools: Discovery, validation, qualification and use, Nat. Rev. Rheumatol, vol.14, pp.354-362, 2018.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, O. .;-aren-frontera, B. Melichar et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N. Engl. J. Med, vol.378, pp.1277-1290, 2018.

A. Rheinlander and B. Schraven, Bommhardt, U. CD45 in human physiology and clinical medicine, Immunol. Lett, vol.196, pp.22-32, 2018.

P. Wu, D. Wu, L. Li, Y. Chai, and J. Huang, PD-L1 and Survival in Solid Tumors: A Meta-Analysis, PLoS ONE, vol.10, 2015.

R. H. Thompson, M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong et al., Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma, Cancer, vol.104, pp.2084-2091, 2005.

R. H. Thompson, H. Dong, C. M. Lohse, B. C. Leibovich, M. L. Blute et al., PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.13, pp.1757-1761, 2007.

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-571, 2014.

B. Guertl, U. Senanayake, E. Nusshold, I. Leuschner, S. Mannweiler et al., Lim1, an embryonal transcription factor, is absent in multicystic renal dysplasia, but reactivated in nephroblastomas, Pathobiology, vol.78, pp.210-219, 2011.

I. Hamaidi, C. Coquard, S. Danilin, V. Dormoy, C. Beraud et al., The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma, Oncogene, vol.38, pp.60-72, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02431944

C. T. Schnizlein-bick, F. F. Mandy, M. R. O'gorman, H. Paxton, J. K. Nicholson et al., Use of CD45 gating in three and four-color flow cytometric immunophenotyping: Guideline from the National Institute of Allergy and Infectious Diseases, Division of AIDS, Cytometry, vol.50, pp.46-52, 2002.

I. Zerdes, A. Matikas, J. Bergh, G. Z. Rassidakis, and T. Foukakis, Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: Biology and clinical correlations, Oncogene, vol.37, pp.4639-4661, 2018.

Y. Wang, X. Y. Wang, J. R. Subjeck, P. A. Shrikant, and H. L. Kim, Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines, Br. J. Cancer, vol.104, pp.643-652, 2011.

. R-core-team, R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing, p.17, 2018.

R. Dienstmann and J. Tabernero, Cancer: A precision approach to tumour treatment, Nature, vol.548, pp.40-41, 2017.

X. Jiang, Y. D. Seo, J. H. Chang, A. Coveler, E. N. Nigjeh et al., Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment, vol.6, 2017.